Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
持股变动管理规定
Regulatory Filings Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 持股变动管理规定' which translates to 'Yunnan Biovalley Pharmaceutical Co., Ltd. Shareholding Change Management Regulations'. It details internal rules and regulations regarding the management of shareholding changes by the company's controlling shareholders, directors, supervisors, and senior management. It includes provisions on shareholding limits, prohibited behaviors, reporting requirements, and compliance with relevant laws and stock exchange rules. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings release, no merger or acquisition activity, and no presentation. The document is a regulatory compliance and governance-related announcement about shareholding management rules. It is not a report but a regulatory filing of internal rules and compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 5227 characters, which is sufficient to contain substantive content, not just a brief announcement or certification.
2023-04-25 Chinese
北京市环球（深圳）律师事务所关于云南生物谷药业股份有限公司 2023 年第二次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of the convening, attendance, and voting procedures of the 2023 second extraordinary general meeting of shareholders of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting notice, attendance, voting results, and compliance with relevant laws and company articles. It does not contain financial statements or financial performance data, nor is it a report of voting results alone. It is a legal opinion related to a shareholders meeting, focusing on procedural legality rather than the meeting materials or voting outcomes themselves. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal procedural filing that does not fit other categories such as AGM Information or Declaration of Voting Results, and it is not a full report or announcement of results but a legal opinion letter.
2023-04-02 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It includes details about the meeting date, location, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The document does not contain financial statements or detailed financial analysis but reports the official voting results and decisions made at the shareholders' meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1427 characters), and it is not merely announcing the availability of a report but providing the voting results themselves. Therefore, the correct classification is DVA with high confidence.
2023-04-02 Chinese
关于拟变更注册地址并修订《公司章程》 的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed change of the company's registered address and the corresponding amendment to the company's articles of association. It includes details about the old and new addresses, the reason for the change, and mentions that the amendment will be submitted to the shareholders' meeting for approval. There is no financial data, audit information, or report content. It is not a full report but a regulatory announcement about corporate governance changes related to company registration and articles of association. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-03-14 Chinese
合同管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 合同管理制度' which translates to 'Contract Management System of Yunnan Biological Valley Pharmaceutical Co., Ltd.' It is a detailed internal policy document outlining the company's contract management procedures, responsibilities, approval processes, supervision, and penalties for violations. The document includes references to the board of directors' meeting approving the policy on March 13, 2023, but it is not an announcement of board changes or voting results. It is not a financial report, audit, earnings release, or any form of shareholder meeting material. It is a governance-related document detailing internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4157 characters, which is sufficient for a substantive policy document rather than a brief announcement.
2023-03-14 Chinese
第四届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 4th Board of Directors of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to other announcements for detailed content. The document does not contain financial statements or detailed financial data but focuses on board decisions and governance matters such as changes to company bylaws, management systems, and plans for a shareholder meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (2110 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-03-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.